Liquid-liquid phase separation of protein tau: An emerging process in Alzheimer's disease pathogenesis

Hassan Ainani1, Najat Bouchmaa1, Reda Ben Mrid1

  • 1Institute of Biological Sciences (ISSB), UM6P-Faculty of Medical Sciences (UM6P-FMS), Mohammed VI Polytechnic University, Ben-Guerir, Morocco.

Neurobiology of Disease
|January 26, 2023
PubMed

Insights

Membrane-less organelles form via liquid-liquid phase separation (LLPS). Tau protein

Area of Science:

  • Cell Biology
  • Biochemistry
  • Neuroscience

Background:

  • Cellular compartments, including membrane-less organelles (MLOs), regulate metabolic reactions.
  • MLOs form through liquid-liquid phase separation (LLPS), involving molecular interactions like protein-RNA.
  • Disruptions in MLOs are linked to various pathologies, including neurodegenerative diseases.

Purpose of the Study:

  • To review factors influencing liquid droplet formation in cells.
  • To highlight the role of tau protein phase separation in Alzheimer's disease (AD).
  • To discuss potential therapeutic strategies targeting tau aggregation in AD.

Main Methods:

  • Literature review of MLO formation and function.
  • Analysis of studies on tau protein phase separation.
  • Exploration of therapeutic interventions for AD.

Main Results:

  • MLOs form via LLPS, driven by molecular interactions and influenced by factors like crowding agents and phosphorylation.
  • Tau protein can undergo LLPS to form tau droplets, which may mature into insoluble aggregates.
  • Tau aggregation via phase separation is implicated in Alzheimer's disease pathogenesis.

Conclusions:

  • Understanding LLPS and MLOs is crucial for cellular function.
  • Tau protein phase separation is a key mechanism in Alzheimer's disease.
  • Targeting tau aggregation through therapeutic strategies offers potential for AD treatment.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.7K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
596
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
237